stockrow
Friday 6 November 2026
Export QGEN’s income statement to Excel — free account
QIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
50.31
0.55
−1.08%
Follow QGEN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
20.03 | 20.91 | 23.48 | 24.28 |
+8 more quarters Free account |
P/S ratio |
3.84 | 3.95 | 4.92 | 4.68 | |
P/FCF ratio |
18.31 | 20.52 | 22.99 | 20.51 | |
P/Operating CF |
40.20 | 82.37 | 54.66 | 58.72 | |
P/B ratio |
2.40 | 2.49 | 2.72 | 2.66 | |
Price to Tangible BV |
25.86 | 30.90 | 14.88 | 12.15 | |
EV/Sales |
4.25 | 4.66 | 5.43 | 4.89 | |
EV/EBITDA |
13.70 | 15.31 | 17.10 | 14.87 | |
EV/Operating CF |
13.63 | 15.91 | 17.33 | 15.40 | |
EV/FCF |
20.24 | 24.24 | 25.35 | 21.43 | |
Quick Ratio |
2.04 | 2.18 | 2.93 | 2.12 | |
Current Ratio |
2.85 | 3.21 | 3.90 | 2.60 | |
Net Debt/EBITDA |
4.63 | 7.34 | 3.71 | 2.41 | |
Debt/Assets |
27.91% | 28.48% | 26.34% | 32.46% | |
Debt/Equity |
0.49 | 0.49 | 0.44 | 0.58 | |
Asset Turnover |
0.36 | 0.37 | 0.35 | 0.32 | |
Operating CF/Net income |
1.94 | 1.48 | 1.74 | 1.27 | |
Capex/Depreciation |
(0.85) | (0.94) | (1.42) | (0.97) | |
Interest Coverage |
13.21 | 7.64 | 9.81 | 15.72 | |
Research and Development Expense of Revenue |
9.43% | 9.80% | 8.74% | 9.15% | |
Selling, General and Administrative Expense of Revenue |
27.43% | 28.92% | 28.47% | 26.87% | |
Intangible Assets out of Total Assets |
0.52 | 0.53 | 0.49 | 0.44 | |
Share Based Compensation of Revenue |
1.30% | 1.96% | 3.07% | 2.01% | |
Graham Net Nets |
(0.11) | (0.11) | (0.05) | (0.04) | |
Graham Number |
26.73 | 26.33 | 28.09 | 27.78 | |
Earnings Yield |
4.99% | 4.78% | 4.26% | 4.12% | |
Free Cash Flow Yield |
5.46% | 4.87% | 4.35% | 4.88% | |
Revenue per Share |
2.59 | 2.38 | 2.49 | 2.59 | |
Operating CF per Share |
0.97 | 0.49 | 0.87 | 0.80 | |
Capex per Share |
(0.21) | (0.23) | (0.33) | (0.24) | |
Free Cash Flow per Share |
0.76 | 0.25 | 0.54 | 0.56 | |
Cash per Share |
3.85 | 3.12 | 5.06 | 8.20 | |
Shareholders Equity per Share |
16.27 | 16.09 | 17.39 | 17.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.27 | 16.09 | 17.39 | 17.71 | |
Free Cash Flow |
157.32 | 52.15 | 116.55 | 114.57 | |
Working Capital |
1,075.18 | 1,061.14 | 1,482.94 | 1,557.53 | |
Capital Expenditures |
(43.37) | (48.48) | (71.58) | (50.45) | |
Net Current Asset Value |
(874.83) | (910.10) | (508.00) | (373.14) | |
EV/EBIT |
20.02 | 22.51 | 24.34 | 20.86 | |
Capex to Sales |
0.08 | 0.10 | 0.13 | 0.09 | |
Price to Operating Income |
18.11 | 19.06 | 22.07 | 19.96 | |
| Other line items | |||||
Average Receivables |
387.80 | 368.66 | 375.94 | 360.57 | |
Average Payables |
80.71 | 73.98 | 77.96 | 76.89 | |
Average Inventory |
301.95 | 295.49 | 290.57 | 305.96 | |
Average Assets |
5,856.48 | 5,663.72 | 5,985.43 | 6,411.85 | |
Average Common Equity |
3,431.62 | 3,369.79 | 3,672.75 | 3,589.70 |
Columns are period end dates · fundamentals updated 25 Oct 2026